KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.

Robert J Motzer, Axel Bex, Paul Russo, Yoshihiko Tomita, Hernan Javier Cutuli, Carlos Rojas, Marine Gross-Goupil, Giovanni Schinzari, Bohuslav Melichar, Philippe Barthélémy, Abraham Ruiz Garcia, Jeffrey Sosman, Marc-Oliver Grimm, Jeffrey C Goh, Cristina Suarez, Christian K Kollmannsberger, Suresh G Nair, Brian M Shuch, Jian Huang, Burcin Simsek, Julia Spiridigliozzi, Chung-Wei Lee, Maximiliano van Kooten Losio, Viktor Grünwald

J Clin Oncol 43(2) 189-200

PMID39303200
PMCIDPMC11709003
DOI10.1200/JCO.24.00773
发表日期2024-09-20
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

PURPOSE: CheckMate 914 is a two-part, randomized phase III trial evaluating adjuvant nivolumab plus ipilimumab (part A) or adjuvant nivolumab monotherapy (part B) versus placebo in mutually exclusive populations of patients with localized renal cell carcinoma (RCC) at high risk of postnephrectomy recurrence. Part A showed no disease-free survival (DFS) benefit for adjuvant nivolumab plus ipilimumab versus placebo. We report results from part B. METHODS: Patients were randomly assigned (2:1:1) to nivolumab (240 mg once every 2 weeks for up to 12 doses), placebo, or nivolumab (240 mg once every 2 weeks for up to 12 doses) plus ipilimumab (1 mg/kg once every 6 weeks for up to four doses). The planned treatment duration was 24 weeks (approximately 5.5 months). The primary end point was DFS per blinded independent central review (BICR) for nivolumab versus placebo; safety was a secondary end point. RESULTS: Overall, 825 patients were randomly assigned to nivolumab (n = 411), placebo (n = 208), or nivolumab plus ipilimumab (n = 206). With a median follow-up of 27.0 months (range, 18.0-42.4), the primary end point of improved DFS per BICR with nivolumab versus placebo was not met (hazard ratio [HR], 0.87 [95% CI, 0.62 to 1.21]; P = .40); the median DFS was not reached in either arm, and 18-month DFS rates were 78.4% versus 75.4%. The HR for DFS per investigator was 0.80 (95% CI, 0.58 to 1.12; P = .19). Grade 3-4 all-cause adverse events (AEs) occurred in 17.2%, 15.0%, and 28.9% of patients with nivolumab, placebo, and nivolumab plus ipilimumab, respectively. Any-grade treatment-related AEs led to discontinuation in 9.6%, 1.0%, and 28.4%, respectively. CONCLUSION: Part B of CheckMate 914 did not meet the primary end point of improved DFS for nivolumab versus placebo in patients with localized RCC at high risk of postnephrectomy recurrence.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure1 个面板

FIG 2.

DFS per BICR in the overall ITT population for nivolumab versus placebo. DFS was estimated in all randomly assigned patients and defined as the time from random assignment to the development of local disease recurrence, distant metastasis, or death, whichever came first. BICR, blinded independent central review; DFS, disease-free survival; HR, hazard ratio; ITT, intention-to-treat; NE, not estimable; NR, not reached.

DFS_Probability_vs._Time

Disease-Free Survival

FIG 2. · Panel DFS_Probability_vs._Time

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel DFS_Probability_vs._Time 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure3 个面板

FIG 4.

DFS per BICR in pooled subgroups of interest with sarcomatoid features (A), PD-L1 expression ≥1% (B), or pT4, any grade (N0M0) or any pT, any grade (N1M0) staging (C). Ad hoc analyses were conducted using pooled data from parts A and B of the study to compare DFS per BICR with immunotherapy (nivolumab plus ipilimumab in part A and either nivolumab or nivolumab plus ipilimumab in part B) versus placebo (from parts A and B) in select subgroups of patients. DFS was estimated in all randomly assigned patients and defined as the time from random assignment to the development of local disease recurrence, distant metastasis, or death, whichever came first. PD-L1 testing was performed locally (Labcorp) using a validated tumor proportion score–based PD-L1 immunohistochemical assay (Dako PD-L1 IHC 28-8 pharmDx). BICR, blinded independent central review; DFS, disease-free survival; HR, hazard ratio; NE, not estimable; NR, not reached.

A

DFS

FIG 4. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

DFS

FIG 4. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

DFS

FIG 4. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.CONSORT diagram. AE, adverse event; ITT, intention-to-treat. a Three patients were excluded before random assignment due to COVID-19 disease. b Includes patients who withdrew consent or requested to discontinue study treatment. c Four patients in the nivolumab arm, two in the placebo arm, and two in the nivolumab plus ipilimumab arm discontinued treatment due to COVID-19 disease.
非 KM Figure
FIG 3.DFS per BICR in key subgroups for nivolumab versus placebo. DFS was estimated in all randomly assigned patients and defined as the time from random assignment to the development of local disease recurrence, distant metastasis, or death, whichever came first. The influence of demographic and baseline clinical characteristics on DFS among randomly assigned patients was assessed via exploratory subgroup analyses. HRs were not computed for subgroups with <11 patients per treatment arm (except for age, region, and sex). The statistical analysis plan prespecified that subgroup analyses for stratification factors (TNM staging and type of nephrectomy) would be based on case report form data. BICR, blinded independent central review; DFS, disease-free survival; HR, hazard ratio; ITT, intention-to-treat; LLN, lower limit of normal.
非 KM Figure